Related Experiment Video
Updated: Mar 29, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Clopidogrel Response Variability: Review of the Literature and Practical Considerations
Carrie S Oliphant1, Brian J Trevarrow2, Paul P Dobesh3
1Methodist Healthcare, University Hospital, Memphis, TN, USA Department of Clinical Pharmacy, University of Tennessee College of Pharmacy, Memphis, TN, USA.
Insights
Platelet function testing can identify poor response to clopidogrel, a common issue after acute coronary syndrome. While tailored therapy hasn't consistently reduced events, testing may guide treatment in high-risk patients to prevent stent thrombosis.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is standard post-acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI).
- Despite potent antiplatelet agents, vascular events persist, partly due to variable patient response to therapies like clopidogrel.
- Poor clopidogrel response is linked to increased vascular event risk, prompting investigation into alternative strategies.
Purpose of the Study:
- To review studies on clopidogrel response variability and its clinical implications.
- To discuss strategies for overcoming clopidogrel non-response.
- To provide practical considerations for clinicians regarding antiplatelet therapy management.
Main Methods:
- Review of key studies investigating clopidogrel response variability.
- Analysis of strategies aimed at optimizing antiplatelet therapy.
- Discussion of clinical scenarios for platelet function testing.
Main Results:
- Consistent association found between poor clopidogrel response and increased vascular event risk.
- Studies on tailored antiplatelet therapy (e.g., higher doses, alternative agents) have generally not shown significant clinical event reduction in low-risk populations.
- Platelet function testing may be valuable in specific high-risk patient groups, such as those at risk of stent thrombosis.
Conclusions:
- Platelet function testing can identify patients with inadequate response to clopidogrel.
- While tailored therapy has limitations, testing may be beneficial for selected high-risk patients to ensure treatment efficacy and potentially assess bleeding risk.
- Further research is needed to refine the role of platelet function testing in optimizing antiplatelet therapy.
Abstract:
Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is standard therapy following acute coronary syndrome and percutaneous coronary intervention. Despite the use of potent antiplatelet agents, vascular events continue to occur. Lack of response to clopidogrel therapy has been widely investigated using various methods of platelet function testing. These studies have consistently found an association between poor clopidogrel response and an increased risk of vascular events. Strategies to overcome this problem include higher clopidogrel doses or the use of an alternative P2Y12 agent. To date, the majority of studies investigating tailored antiplatelet therapy have failed to show any reduction in clinical events likely due to the low-risk population studied. Despite this lack of benefit from altering therapy, platelet function testing may be done in certain patient populations. Patients at high risk of deleterious outcomes from stent thrombosis may be an appropriate patient population for platelet function testing to ensure adequate response to therapy. In addition, emerging data suggests a potential role for platelet function testing to assess for bleeding risk. The purpose of this article is to review the key studies demonstrating response variability to clopidogrel therapy, strategies to overcome variability, and practical considerations for the clinician.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
01:24Dosage Regimen: Individualization
01:21Factors Affecting Drug Response: Overview
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems